Alzor CCB Adverse Reactions

Olmesartan medoxomil plus Amlodipine combination: The most commonly reported adverse reactions during treatment with Olmesartan medoxomil plus Amlodipine combination are peripheral oedema (11.3%), headache (5.3%) and dizziness (4.5%).
Adverse reactions from Olmesartan medoxomil plus Amlodipine combination in clinical trials, post-authorization safety studies and spontaneous reporting are summarized in the tables as follows as well as adverse reactions from the individual components olmesartan medoxomil and amlodipine based on the known safety profile of these substances.
The following terminologies have been used in order to classify the occurrence of adverse reactions: Very common (≥1/10), Common (≥1/100 to <1/10), Uncommon (≥1/1,000 to <1/100), Rare (≥1/10,000 to <1/1,000), Very rare (<1/10,000), not known (cannot be estimated from the available data). (See Tables a and b.)

Click on icon to see table/diagram/image


Click on icon to see table/diagram/image

Single cases of rhabdomyolysis have been reported in temporal association with the intake of angiotensin II receptor blockers. Single cases of extrapyramidal syndrome have been reported in patients treated with amlodipine.